Emerging Nanomaterials and Nanoformulations for Neurodegenerative Disease Treatments
A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".
Deadline for manuscript submissions: 20 September 2026 | Viewed by 200
Special Issue Editors
Interests: metal oxide nanoparticles; phytochemistry; diabetes treatment; nanochemistry; bionanomaterials
Special Issues, Collections and Topics in MDPI journals
Interests: aptamers; nanoscience; nanomedicine; electrochemical biosensors; fluorescent biosensors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and related disorders, remain among the most pressing global healthcare challenges due to their progressive nature and the lack of effective disease-modifying therapies. Over the past two decades, advances in nanoscience have transformed biomedical research by enabling precise control over material size, surface chemistry, and functionality. Nanomaterials offer unique advantages such as improved drug stability, enhanced bioavailability, and the ability to cross complex biological barriers like the blood–brain barrier, which has historically limited effective neurological treatments.
Recent developments in inorganic nanoparticles, polymeric systems, biomimetic carriers, and multifunctional theranostic platforms highlight the growing importance of nanoformulations in addressing challenges related to targeted delivery, imaging, and controlled therapeutic release. There is a strong need to consolidate emerging knowledge and experimental strategies in this rapidly evolving field, as interdisciplinary research in materials science, biotechnology, and artificial intelligence expands.
This Special Issue aims to provide a comprehensive platform for researchers working at the interface of nanotechnology and neuroscience to present innovative materials, formulations, and translational strategies for neurodegenerative disease treatment. The issue will emphasize novel synthesis routes, functionalization approaches, biocompatibility assessment, and scalable nanoformulation design. The collection seeks to accelerate the translation of nanotechnology-based therapies from laboratory research to real-world clinical applications by bringing together contributions from materials scientists, chemists, biomedical engineers, and clinicians.
We encourage submissions covering advanced nanomaterial design and emerging therapeutic concepts, including multifunctional nanoparticles for targeted drug delivery, nanotheranostic platforms integrating imaging and therapy, green and sustainable nanomaterial synthesis, smart nanoformulations for controlled release, AI-assisted nanomaterial optimization, and bioresponsive systems for precision medicine. Studies addressing blood–brain barrier penetration, neuroinflammation modulation, oxidative stress regulation, and neuroprotective strategies are particularly welcome, reflecting current research priorities in nanomedicine and brain disease treatment.
This Special Issue invites high-quality original research articles, review papers, short communications, and perspectives focused on innovative nanomaterials and nanoformulations for neurodegenerative disorders. Contributions addressing synthesis, characterization, mechanistic studies, in vitro and in vivo evaluations, translational challenges, and interdisciplinary approaches are highly encouraged. Submissions that provide standardized methodologies, scalable fabrication techniques, or clinically relevant insights will be especially valuable in advancing this rapidly evolving research field.
Dr. Jaison Jeevanandam
Prof. Dr. Michael Danquah
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative diseases
- nanomaterials
- nanoformulations
- nanotoxicity
- therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
